Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Advanced Research & Education LLC

Neither a doctor nor a teaching hospital

Research payments

$11,377,025

72 payments

Through program year 2025, Center for Advanced Research & Education LLC is reported as receiving $11,377,025 in research payments, across 72 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,723,872 15
2024 Research $2,163,840 17
2023 Research $3,943,112 15
2022 Research $1,211,122 16
2021 Research $531,489 5
2020 Research $720,310 3
2019 Research $83,280 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $11,375,947 67 payments
  2. Genentech, Inc. $1,078 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $2,190,966 2 payments
  2. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,567,121 4 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,419,446 6 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $959,186 6 payments
  5. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $871,776 5 payments
  6. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $817,318 2 payments
  7. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $764,841 3 payments
  8. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $460,321 2 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $379,180 6 payments
  10. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $359,882 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record